Clinical Trial Update: A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MT1013 for safety, tolerability, and efficacy in patients with secondary hyperparathyroidism due to chronic kidney disease on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• MT1013

Snippet

Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Conditions: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | Phase 2 | Status: COMPLETED